articleTop 1% cited

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of Clinical Oncology · 2003 · Vol. 21(17) · pp. 3194–3200

Robert F. Ozols✉(Gynecologic Oncology Group)Brian N. Bundy(Gynecologic Oncology Group)Benjamin E. Greer(Gynecologic Oncology Group)Jeffrey M. Fowler(Gynecologic Oncology Group)Daniel L. Clarke‐Pearson(Gynecologic Oncology Group)Robert A. Burger(Gynecologic Oncology Group)Robert S. Mannel(Gynecologic Oncology Group)Koen DeGeest(Gynecologic Oncology Group)Ellen M. Hartenbach(Gynecologic Oncology Group)Rebecca N. Baergen(Gynecologic Oncology Group)

View via DOI Publisher page

Abstract

In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel.

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Chemotherapy-induced organ toxicity mitigationMedicineCarboplatinPaclitaxelGynecologic oncologyRegimenOvarian cancerInternal medicineCisplatinOncologyLeukopenia

MeSH terms

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyFemaleHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsProportional Hazards ModelsSurvival AnalysisCarboplatinTreatment Outcome

Citations

2,051

FWCI

89.84

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Epithelial ovarian cancer: Evolution of management in the era of precision medicine